Gan & Lee Pharmaceuticals Co., Ltd. Class ASSE: 603087

Announcement on Completion of Administration of the First Subject in Phase III Clinical Trial of New Indication of Bofanglutide (GZR18) Injection

· Issued by Gan & Lee Pharmaceuticals Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Completion of Administration of the First Subject in Phase III Clinical Trial of New Indication of Bofanglutide (GZR18) Injection

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis